Hyperpersonalization, or super-targeted marketing, is a growing pharma opportunity, agency says

Hyperpersonalized or super-targeted marketing to small audiences is gaining traction in pharma and healthcare.

More personalized medicines also means more personalized marketing—and the hyperpersonalization trend goes to extremes. Using advanced data and analytics, marketers can whittle down their targets and tailor messages to consumer audiences sometimes as small as one person.

Marketers gather data from multiple sources, crunch it, and then identify small groups that could be receptive to specific messaging. It’s already beginning to happen in areas like rare diseases, says specialty agency Cambridge BioMarketing.

RELATED: AstraZeneca lobbies for personalized asthma care with new visual snapshot tool

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Where we’re going with hyper-personalization is using the systems, the platforms and the technology to allow us to dynamically, and in a predictive manner, serve content to users based on what we’re seeing interests them,” said Annemarie Crivelli, director of digital at Cambridge BioMarketing.

For example, in email marketing, she said, pharma marketers can craft a strategy with a very specific messaging and use segmenting, tagging and targeting to reach each person. Those techniques enable the agency and its pharma clients to “see” what people are doing online in real time and then use predictive and dynamic content to deliver hyperpersonalized emails.

RELATED: Personalization expert Pandora's pharma practice takes off after patient-data partnership

Of course, real time in pharma requires special care. FDA regulations mean that content has to be prescreened and approved for use. Still, it’s not only possible, but more probable, in the coming year as technology and treatments both advance.

“A lot of consumer brands will do this on the fly, monitoring and writing content on the fly based on what they’re seeing, but that’s harder to do in pharma,” Crivelli said. “For pharma, the success is in the mapping and planning out of what do we need to say and what are all the options, and then getting them pre-approved by regulatory to build a system can deliver as folks are consuming content.”

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.